drugset / Trial / NCT06337643
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
RandomizedSequentialTriple-blindPrevention
Summary
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
Timeline
- Start
- 2023-03-07
- Primary completion
- 2024-04-16
- Completion
- 2024-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVX01 | Vaccine | 10 ug | Intramuscular |
| Subject | MVX01 | Vaccine | 30 ug | Intramuscular |
| Subject | MVX01 | Vaccine | 60 ug | Intramuscular |
| Subject | MVX01 | Vaccine | 90 ug | Intramuscular |
Indications
No indication recorded.